The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | What do community oncologists need to know about using MRD in multiple myeloma?
In this video, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, briefly comments on the importance of adhering to guidelines when using measurable residual disease (MRD) as a biomarker in multiple myeloma (MM), emphasizing that compliance with methodology, sample quality, and data interpretation is crucial to achieving optimal patient outcomes. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Now that MRD is becoming so important in myeloma, both in terms of primary endpoint in clinical trials, but also potentially as a biomarker driving treatment decisions, my take-home message is to comply with the guidelines. If we are using more and more MRD in routine practice, please adhere to the guidelines in terms of methodology, sample quality, and data interpretation...
Now that MRD is becoming so important in myeloma, both in terms of primary endpoint in clinical trials, but also potentially as a biomarker driving treatment decisions, my take-home message is to comply with the guidelines. If we are using more and more MRD in routine practice, please adhere to the guidelines in terms of methodology, sample quality, and data interpretation. This is paramount to achieve the best outcomes using MRD as a biomarker.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Bristol Myers Squibb/Celgene, Janssen, Sanofi, and Takeda: Consultancy; Adaptive, Amgen, Becton Dickinson, Bristol Myers Squibb/Celgene, Janssen, Merck, Novartis, Roche, Sanofi and Takeda: Honoraria; Aztra Zeneca, Bristol Myers Squibb/Celgene, EngMab, Roche, Sanofi, and Takeda: Research Funding.
